Manon Allaire

1.7k total citations · 1 hit paper
47 papers, 846 citations indexed

About

Manon Allaire is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Manon Allaire has authored 47 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hepatology, 27 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in Manon Allaire's work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Liver Disease Diagnosis and Treatment (21 papers) and Liver Disease and Transplantation (16 papers). Manon Allaire is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Liver Disease Diagnosis and Treatment (21 papers) and Liver Disease and Transplantation (16 papers). Manon Allaire collaborates with scholars based in France, Italy and United States. Manon Allaire's co-authors include Sophie Lotersztajn, Patrice Codogno, Pierre‐Emmanuel Rautou, Jean‐Charles Nault, Dominique Thabut, Hélène Gilgenkrantz, Mathilde Wagner, Marika Rudler, Claire Goumard and Olivier Scatton and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Manon Allaire

39 papers receiving 836 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Autophagy in liver diseases: Time for translation?

2019 294 citations Manon Allaire, Sophie Lotersztajn et al. Journal of Hepatology profile →

Peers

Manon Allaire

EPIDE

HEPAT

SURGE

Andrea Marengo Italy

Natascha Roehlen Germany

Julia Wattacheril United States

Tejasav S. Sehrawat United States

Carla Montironi Spain

Joeri Lambrecht Germany

Svenja Sydor Germany

Massih Ningarhari France

Peri Kocabayoglu Germany

Andrea Marengo Italy

Manon Allaire

544 ×1.1

EPIDE

296 ×0.7

HEPAT

265 ×1.4

91 ×0.8

SURGE

159 ×1.5

Citations per year, relative to Manon Allaire Manon Allaire (= 1×) peers Andrea Marengo

Countries citing papers authored by Manon Allaire

Since Specialization

Citations

This map shows the geographic impact of Manon Allaire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manon Allaire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manon Allaire more than expected).

Fields of papers citing papers by Manon Allaire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manon Allaire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manon Allaire. The network helps show where Manon Allaire may publish in the future.

Co-authorship network of co-authors of Manon Allaire

This figure shows the co-authorship network connecting the top 25 collaborators of Manon Allaire. A scholar is included among the top collaborators of Manon Allaire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manon Allaire. Manon Allaire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allaire, Manon, Julien Edeline, P. Merle, et al.. (2025). 1487P Extended follow-up at 42 months of atezolizumab–bevacizumab in advanced HCC: Insights from the CHIEF prospective study. Annals of Oncology. 36. S829–S829.

Allaire, Manon & Dominique Thabut. (2024). Comment on Wu et al. Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma. Cancers 2023, 15, 2480. Cancers. 16(3). 661–661.

Allaire, Manon, Philippe Sultanik, & Dominique Thabut. (2024). Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC. JHEP Reports. 6(8). 101120–101120. 2 indexed citations

Roux, Charles, M. Soret, Mathilde Wagner, et al.. (2024). Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival. Clinics and Research in Hepatology and Gastroenterology. 48(2). 102282–102282. 7 indexed citations

Sultanik, Philippe, Claudia Campani, Charles Roux, et al.. (2024). Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Digestive and Liver Disease. 56(9). 1621–1630. 7 indexed citations

Galy–Fauroux, Isabelle, et al.. (2023). Complete response with sorafenib after immune-induced hepatitis with atezolizumab/bevacizumab for advanced hepatocellular carcinoma, synergic effect?. Clinics and Research in Hepatology and Gastroenterology. 47(9). 102210–102210.

Campani, Claudia, Manon Allaire, Philippe Sultanik, et al.. (2023). Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab. Hepatology. 79(1). 49–60. 14 indexed citations

Wagner, Mathilde, Claire Goumard, Olivier Scatton, et al.. (2023). Portal‐hypertension features are associated with ascites occurrence and survival in patients with hepatocellular carcinoma treated by external radiotherapy. United European Gastroenterology Journal. 11(10). 985–997. 3 indexed citations

Couty, Jean‐Pierre, Philippe Sultanik, Claudia Campani, et al.. (2023). Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC. Clinics and Research in Hepatology and Gastroenterology. 47(8). 102199–102199. 1 indexed citations

10.

Allaire, Manon, Morgane Mabire, Adel Hammoutène, et al.. (2023). Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regeneration. JHEP Reports. 5(8). 100794–100794. 11 indexed citations

11.

Merle, Philippe, Jean‐Frédéric Blanc, Julien Edeline, et al.. (2023). Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Digestive and Liver Disease. 55(4). 464–470. 18 indexed citations

12.

Sultanik, Philippe, Lorraine Blaise, Mathilde Wagner, et al.. (2022). A history of variceal bleeding is associated with further bleeding under atezolizumab–bevacizumab in patients with HCC. Liver International. 42(12). 2843–2854. 19 indexed citations

13.

Campani, Claudia, Lorraine Blaise, Nathalie Ganne‐Carrié, et al.. (2022). Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver International. 43(3). 708–717. 27 indexed citations

14.

Allaire, Manon, Jordi Bruix, Marko Korenjak, et al.. (2022). What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Reports. 4(12). 100578–100578. 30 indexed citations

15.

Allaire, Manon, et al.. (2021). “De novo” cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed!. Clinics and Research in Hepatology and Gastroenterology. 46(4). 101827–101827.

16.

Allaire, Manon, Anna Sessa, J.F. Cadranel, & Pascal Lebray. (2021). Reply to: “Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?”. JHEP Reports. 3(4). 100327–100327. 1 indexed citations

17.

Cluzel, Philippe, et al.. (2021). TIPS for patients with early HCC: A bridge to liver transplantation. Clinics and Research in Hepatology and Gastroenterology. 46(8). 101790–101790. 8 indexed citations

18.

Ollivier‐Hourmand, Isabelle, et al.. (2020). Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients. BMC Infectious Diseases. 20(1). 522–522. 4 indexed citations

19.

Allaire, Manon & Hélène Gilgenkrantz. (2018). The impact of steatosis on liver regeneration. Hormone Molecular Biology and Clinical Investigation. 41(1). 17 indexed citations

20.

Allaire, Manon & Jean‐Charles Nault. (2016). Molecular targets for HCC and future treatments. Journal of Hepatology. 66(1). 234–235. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact